Table 1. Clinicopathological characteristics of the ESCC cohort.
All patients | Patients with Stage I-II disease | Patients without lymph node metastasis | ||||
---|---|---|---|---|---|---|
n | % | n | % | n | % | |
Sex | ||||||
Female | 46 | 16.5 | 35 | 20.8 | 29 | 20 |
Male | 232 | 83.5 | 133 | 79.2 | 116 | 80 |
Age | ||||||
<60 | 116 | 41.7 | 62 | 36.9 | 51 | 35.2 |
≥60 | 162 | 58.3 | 106 | 63.1 | 94 | 64.8 |
Smoking | ||||||
No | 162 | 58.3 | 110 | 65.5 | 95 | 65.5 |
Yes | 115 | 41.4 | 57 | 33.9 | 49 | 33.8 |
Differentiation | ||||||
Well | 7 | 2.5 | 4 | 2.4 | 4 | 2.8 |
Moderate | 156 | 56.1 | 97 | 57.7 | 85 | 58.6 |
Poor | 115 | 41.4 | 67 | 39.9 | 56 | 38.6 |
Invasive depth | ||||||
I | 89 | 32 | 82 | 48.8 | 61 | 42.1 |
II | 189 | 68 | 86 | 51.2 | 84 | 57.9 |
Vessel involvement | ||||||
No | 227 | 81.7 | 157 | 93.5 | 137 | 94.5 |
Yes | 51 | 18.3 | 11 | 6.5 | 8 | 5.5 |
Nerve involvement | ||||||
No | 205 | 73.7 | 137 | 81.5 | 116 | 80 |
Yes | 73 | 26.3 | 31 | 18.5 | 29 | 20 |
Lymph node metastasis | ||||||
No | 145 | 52.2 | 135 | 80.4 | ||
Yes | 133 | 47.8 | 33 | 19.6 | ||
Tumor site | ||||||
Upper | 13 | 4.7 | 8 | 4.8 | 7 | 4.8 |
Middle | 131 | 47.1 | 83 | 49.4 | 73 | 50.3 |
Low | 123 | 44.2 | 66 | 39.3 | 54 | 37.2 |
Clinical stage | ||||||
I-II | 168 | 60.4 | 135 | 93.1 | ||
III-Iva | 110 | 39.6 | 10 | 6.9 | ||
tPD-L1 ≥1% | ||||||
No | 137 | 49.3 | 88 | 52.4 | 73 | 50.3 |
Yes | 141 | 50.7 | 80 | 47.6 | 72 | 49.7 |
tPD-L1 ≥5% | ||||||
No | 153 | 55 | 96 | 57.1 | 78 | 53.8 |
Yes | 125 | 45 | 72 | 42.9 | 67 | 46.2 |
tPD-L1 ≥10% | ||||||
No | 180 | 64.7 | 116 | 69 | 95 | 65.5 |
Yes | 98 | 35.3 | 52 | 31 | 50 | 34.5 |
tPD-L1 ≥20% | ||||||
No | 199 | 71.6 | 124 | 73.8 | 102 | 70.3 |
Yes | 79 | 28.4 | 44 | 26.2 | 43 | 29.7 |
tPD-L1 ≥30% | ||||||
No | 221 | 79.5 | 134 | 79.8 | 113 | 77.9 |
Yes | 57 | 20.5 | 34 | 20.2 | 32 | 22.1 |
tPD-L1 ≥50% | ||||||
No | 233 | 83.8 | 142 | 84.5 | 121 | 83.4 |
Yes | 45 | 16.2 | 26 | 15.5 | 24 | 16.6 |
sPD-L1 ≥1% | ||||||
No | 162 | 58.3 | 97 | 57.7 | 88 | 60.7 |
Yes | 116 | 41.7 | 71 | 42.3 | 57 | 39.3 |
sPD-L1 ≥5% | ||||||
No | 171 | 61.5 | 103 | 61.3 | 91 | 62.8 |
Yes | 107 | 38.5 | 65 | 38.7 | 54 | 37.2 |
sPD-L1 ≥10% | ||||||
No | 235 | 84.5 | 142 | 84.5 | 121 | 83.4 |
Yes | 43 | 15.5 | 26 | 15.5 | 24 | 16.6 |
sPD-L1 ≥20% | ||||||
No | 236 | 84.9 | 142 | 84.5 | 121 | 83.4 |
Yes | 42 | 15.1 | 26 | 15.5 | 24 | 16.6 |
sPD-L1 ≥30% | ||||||
No | 249 | 89.6 | 150 | 89.3 | 128 | 88.3 |
Yes | 29 | 10.4 | 18 | 10.7 | 17 | 11.7 |
sPD-L1 ≥50% | ||||||
No | 260 | 93.5 | 157 | 93.5 | 134 | 92.4 |
Yes | 18 | 6.5 | 11 | 6.5 | 11 | 7.6 |
Invasive depth I, tumor invasion confined to muscularis; Invasive depth II, tumor invasion beyond the muscularis.
tPD-L1, Tumoral PD-L1 expression; sPD-L1, Stromal PD-L1 expression.